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Abstract Tritium labelled (x 1.1 MBq/17.7 Wg/kg) and
unlabelled 8-iso-PGF2K (43 Wg/kg) were administered intrave-
nously to female rabbits and frequent blood and continuous
urinary samples were collected up to 4 h. The total radioactivity
was lost rapidly from the circulation. About 80% of the total
radioactivity was found in urine within 4 h. The plasma half-life
of 8-iso-PGF2K is found to be 1 min at the distribution phase. The
terminal elimination phase half-life was about 4 min. At 1.5 min
after administration 64%, 19% and 13% of the plasma radio-
activity represented 8-iso-PGF2K, 15-keto-8-iso-PGF2K and L-
oxidised products, respectively. The values for 20-min plasma
were 5%, 2% and 88%. The radiochromatograms from 10 min^4
h urinary samples were dominated by more polar L-oxidised
products. K-Tetranor-15-keto-13,14-dihydro-8-iso-PGF2K was
identified as a major urinary metabolite.Thus, 8-iso-PGF2K
metabolises in the rabbit mainly to several degraded polar
metabolites through dehydrogenation at C-15, reduction of v13-
double bond and L-oxidation, and excretes efficiently into the
urine.
z 1998 Federation of European Biochemical Societies.
Key words: Metabolism; Isoprostane; 8-iso-Prostaglandin
F2K ; Eicosanoid; Pharmacokinetics; Lipid peroxidation
1. Introduction
Free radicals are believed to be involved in the aging proc-
ess as well as in a number of diseases including atherosclero-
sis, diabetes, cancer, Alzheimer’s disease, etc. [1^5]. Non-en-
zymatic lipid peroxidation through free radical catalysis of
unsaturated fatty acid oxidation is presumed to be implicated
in several diseases involving oxidative injury. Isoprostanes, a
series of newly discovered prostaglandin like compounds, are
biosynthesised in vivo through free radical oxidation of arach-
idonic acid, circulate in peripheral blood and are excreted in
urine in man and animals [6^9]. 8-Iso-prostaglandin F2K (8-
iso-PGF2K) which is a major isoprostane and exhibits potent
biological activity is elevated in several diseases that are
shown to be associated with various forms of oxidant injury.
These include smoking, diabetes, liver cirrhosis, vascular re-
perfusion and excess alcohol intake [10^14]. Occurrence of F-
ring isoprostane metabolites in human urine has previously
been reported [15]. However, a systematic metabolism study
of 8-iso-PGF2K is lacking. In this study, the in vivo metabo-
lism of 8-iso-PGF2K in the rabbit is investigated.
2. Materials and methods
2.1. Materials
Unlabelled 8-iso-PGF2K, other related isoprostanes and prostaglan-
dins were purchased from Cayman Chemicals, Ann Arbor, MI, USA.
Tris-HCl, Tris-base, EDTA-disodium salt and bovine-Q-globulin were
purchased from Sigma Chemicals (St. Louis, MO, USA). Instagel
scintillation cocktail was obtained from Packard Instruments Co.
(Meriden, CT, USA). Polyethylene glycol (MW 4000) was purchased
from Merck (Germany). Tris-HCl bu¡er 0.05 M, pH 7.8, was used in
the radioimmunoassay (RIA). Bovine Q-globulin 0.5% was prepared in
the RIA bu¡er. Glucose solution was obtained from PharmaciapUp-
john, Uppsala, Sweden. Unlabelled 8-iso-PGF2K standards, tritium
labelled tracer and working antibody solution were prepared in the
RIA bu¡er. The tritium labelled 8-iso-PGF2K (speci¢c activity: 608
GBq/mmol) was synthesized and puri¢ed as described previously
[16,17]. The tritium labelled 8-iso-PGF2K was further diluted with
unlabelled 8-iso-PGF2K to obtain a ¢nal concentration of the sub-
stance which was subsequently administered to the experimental ani-
mals.
2.2. Animal experiment
Two rabbits (New Zealand White rabbits, female, Lidkoºping Kanin
Farm, Lidkoºping, Sweden) of body weight 3.7 and 4.5 kg were used in
this study after acclimatisation to the laboratory conditions. The ani-
mals were anaesthesized by a bolus dose of 3 ml Ketalar and Rompun
(3:1) and further anaesthesia (0.5^1 ml) was given to the animals at
about every half-hour until the end of the experiment. Blood pressure,
respiration, electrolytes and body temperature were checked continu-
ously during the experiments. One ml of saline was given to the
animals through the vena femoralis every half hour. The animals
were killed at the end of the experiment by the administration of an
excess dose of Mebumal Vet (Apoteksbolaget, Sweden).
2.3. Experiment 1
Tritium labelled 8-iso-PGF2K (1.24 MBq/22.2 Wg/kg) in glucose sol-
ution was administered intravenously (vena femoralis) to a rabbit.
Blood samples were collected in heparinised tubes from femoral artery
through a catheter at di¡erent intervals (blood: 1.5, 5, 20, 30, 60, 120
and 240 min; urine: 0^30, 30^60, 60^90, 90^120, 120^180 and 180^
240 min). Plasma was separated and stored frozen at 370‡C until
analysis. Similarly, urinary samples were collected continuously in
portions in glass vials at di¡erent intervals from urinary bladder after
catheterization. The samples were stored frozen at 370‡C until anal-
ysis.
2.4. Experiment 2
Unlabelled 8-iso-PGF2K (43 Wg/kg) in glucose solution was admin-
istered intravenously (vena femoralis) to a rabbit. Blood samples
were collected as in experiment 1 at 0, 1.5, 5, 10, 15, 20, 30, 45, 60,
90, 120 and 150 min after the administration of the substance. Uri-
nary samples were collected similarly as in experiment 1 at di¡erent
intervals (0^10, 10^20, 20^30, 30^60, 60^90, 90^120 and 120^150
min). Samples were treated as before and stored frozen at 370‡C
until analysis.
2.5. Experiment 3
After the end of the second experiment tritium labelled 8-iso-PGF2K
(0.9 MBq/13.2 Wg/kg) in glucose solution was administered intrave-
nously (vena femoralis) to the same rabbit. Blood samples were col-
lected as in experiment 1 at 1.5, 5, 10, 15, 20, 30, 45, 60 and 90 min.
Urinary samples were collected at di¡erent intervals of 0^10, 10^20,
20^30, 30^60 and 60^90 min. Samples were treated as before and
stored frozen at 370‡C until analysis.
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2.6. Puri¢cation, separation and identi¢cation
Total radioactivity was counted in all plasma and urinary samples
before chromatography. To extract 8-iso-PGF2K and its metabolites,
the plasma and urinary samples were puri¢ed by using SEP-PAK C18
column containing octadecylsilyl silica gel (Waters Associates, USA)
according to Basu and Kindahl with minor modi¢cations [18]. In
brief, radiolabelled plasma and urinary samples were acidi¢ed to pH
3.5 by 0.1 M HCl. The samples were passed through the SEP-PAK
C18 columns and the columns were eluted with 5 ml of 20% ethanol
and 10 ml of petroleum ether. 8-iso-PGF2K and its metabolites were
eluted with 5 ml of methyl formate. Ten ml of 80% ethanol was used
to elute the rest material from the column. Radioactivity was counted
in all fractions. The major portion of the radioactivity was found in
the methyl formate fractions which were evaporated to dryness under
N2 and dissolved in ethanol. The samples were analysed by RP-HPLC
(Merck-Hitachi L-6000, Germany) using 5 WM Nucleosil C18 column
(Machery and Nagel, Germany) and the products were detected by an
on-line radioactivity detector (Flow-one A-200, Radiomatic Inc.,
USA). Separation of 8-iso-PGF2K and its metabolites was performed
by using a solvent system consisting of 35% acetonitrile and 65%
water containing 0.1% acetic acid (v/v) as previously described for
prostaglandins [19]. Flow rate was constant at 1 ml/min. Fractions
from the major metabolite were collected after RP-HPLC separation,
evaporated under N2 and further puri¢ed by an SP-phase HPLC. This
separation was performed by using a Nucleosil 50-5 column with a
solvent system of 15% isopropanol and 85% hexane with 0.1% acetic
acid (v/v). Flow rate was constant at 1.5 ml/min. Three separate peaks
were obtained from the major peak collected from RP-HPLC (A, Fig.
2, right panel). Both RP- and SP-HPLC fractions from these peaks
were subjected to GC-MS identi¢cation after derivatisation.
2.7. Derivatisation and GC-MS
Urinary samples from HPLC puri¢ed peaks were evaporated to
dryness under N2 and trimethylsilyl ethers were prepared by treatment
with BSTFA and pyridine [20]. Methyl esters were prepared with
diazomethane [20]. A capillary GC (Varian 3100) with a non-polar
column (30 m, DB-5, JpW Scienti¢c, ¢lm, 0.25 Wm; diameter,
0.25 mm, carrier gas He, 15 psi) and an ion trap mass spectrometer
(ITS40, Finnigan MAT) were used [20]. After splitless injections of
samples in heptane, the GC was programmed from 120 to 200‡C with
40‡C/min to 260‡C with 28‡C/min and then to 285‡C with 3‡C/min.
2.8. Radioimmunoassay of 8-iso-PGF2K
The plasma and urinary samples from the pharmacokinetic study
with unlabelled 8-iso-PGF2K were analysed for 8-iso-PGF2K by a
newly developed radioimmunoassay at our laboratory as described
elsewhere [16]. In brief, unextracted plasma and urinary samples
were used in the assay. The cross-reactivity of the 8-iso-PGF2K anti-
body with 15-keto-13,14-dihydro-8-iso-PGF2K, 8-iso-PGF2L, PGF2K,
15-keto-PGF2K, 15-keto-13,14-dihydro-PGF2K, TXB2, 11L-PGF2K,
9L-PGF2K and 8-iso-PGF3K, was, respectively, 1.7, 9.8, 1.1, 0.01,
0.01, 0.1, 0.03, 1.8 and 0.6%. The detection limit of the assay was
about 23 pmol/l.
3. Results
3.1. Pharmacokinetics of 8-iso-PGF2K
The total radioactivity in the plasma samples collected after
intravenous administration of 3.14 MBq 3H-labelled 8-iso-
PGF2K to a rabbit is shown in Fig. 1 (upper panel). Similarly,
the concentration of radioactivity corresponding to 8-iso-
PGF2K levels as calculated in the radiochromatograms after
separation of the substance from the total radioactivity pro¢le
is shown in Fig. 1 (upper panel). The highest level of radio-
activity and 8-iso-PGF2K was found at 1.5 min after the intra-
venous administration of the radiolabelled 8-iso-PGF2K. The
total excretion of radioactivity in urine was about 80% during
4 h after the administration of the tritium labelled 8-iso-
PGF2K.
The appearance and disappearance of 8-iso-PGF2K in the
plasma and urine after intravenous administration of 159 Wg
of unlabelled 8-iso-PGF2K to a rabbit as analysed by the RIA
is shown in Fig. 1 (lower panel). Following 8-iso-PGF2K ad-
ministration, the increase in 8-iso-PGF2K in the circulation
was very rapid. Maximum concentration (1606 nmol/l) in
the peripheral plasma was reached at 1.5 min after the admin-
istration of the substance. The level then decreased rapidly.
Three hours after application the 8-iso-PGF2K level decreased
to 0.1 nmol/l (lower panel, Fig. 1). The urinary concentration
of 8-iso-PGF2K reached its height (161 Wmol/l) at 20 min fol-
lowing the administration of 8-iso-PGF2K. Three hours after
the application the 8-iso-PGF2K levels decreased to 62 nmol/l
(lower panel, Fig. 1). The plasma distribution phase half-life
(K-phase) of 8-iso-PGF2K is found to be about 1 min. The
terminal elimination phase half-life (L-phase) is shown to be
about 4 min.
3.2. Chromatographic pro¢les of [3H]8-iso-PGF2K
Representative chromatographic pro¢les (RP-HPLC) ob-
tained in plasma samples at various times (1.5, 5 and 20
min) after the administration of [3H]8-iso-PGF2K to a rabbit
is shown in Fig. 2 (left panel). Peak 1 chromatographed as 8-
iso-PGF2K, peak 2 as 15-keto-8-iso-PGF2K and peaks with
retention times between 1 and 5 min represented degraded
shorter polar metabolites of 8-iso-PGF2K. About 83, 43 and
2% of the total radioactivity represented unconverted [3H]8-
iso-PGF2K at 1.5, 5 and 20 min, respectively, after the admin-
istration of [3H]8-iso-PGF2K.
Similarly, representative chromatographic pro¢les obtained
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Fig. 1. The kinetics of total radioactivity (open circle) and [3H]8-
iso-PGF2K (solid circle) in plasma following i.v. administration of
0.9 MBq/13.2 Wg/kg (corresponding to 49 Wg) of [3H]8-iso-PGF2K to
a rabbit (upper panel). The kinetics are shown of 8-iso-PGF2K in
plasma (open square) and urine (open triangle) following i.v. admin-
istration of 43 Wg/kg (corresponding to 159 Wg) of unlabelled 8-iso-
PGF2K to a rabbit (lower panel).
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in urinary samples at various times (0^30, 30^60 and 60^90
min) after the administration of [3H]8-iso-PGF2K to a rabbit
are shown in Fig. 2 (right panel). Peak 1 chromatographed as
8-iso-PGF2K and peaks with retention times between 1 and
5 min represented degraded polar metabolites of 8-iso-
PGF2K. About 2 and 7% of the total radioactivity represented
unconverted [3H]8-iso-PGF2K at 0^30 min and 10^20 min
(data not shown), respectively, after the administration of
[3H]8-iso-PGF2K.
3.3. Identi¢cation of L-oxidation metabolites of 8-iso-PGF2K
The RP-HPLC fractions from the urinary major peak (A,
Fig. 2, right panel) separated by SP-HPLC into three major
peaks. All these peaks (peak A from RP-HPLC and three
peaks from SP-HPLC) were analysed by GC-MS as methyl
ester TMS ether derivatives. Except peak A (see below) from
RP-HPLC none of the peaks contained enough quantity of
material for ¢nal structural determination. Thus, no further
¢nal identi¢cation of the other peaks was possible. How-
ever, the mass spectra from these peaks showed that these
peaks contained most probably several L-oxidised prod-
ucts.
3.4. K-Tetranor-15-keto-13,14-dihydro-8-iso-PGF2K
The mass spectrum and derivatised molecular structure of
this metabolite (RP-HPLC, peak A, Fig. 2, C23H46O5Si2) are
shown in Fig. 3. The mass spectrum showed signals at m/z 458
(M) which is in accordance with the expected molecular ion
of this metabolite. Strong signals were obtained at m/z 443
(M 315), 368 (M 390), 353 (M 390+15) indicating cleav-
ages of CH3-, (CH3)3SiO- and (CH3)3SiO-CH3-groups, re-
spectively. K and L cleavages indicating a keto group at C-11
were observed at m/z 387 (M 390+71), 254 (M 390+b+1)
and 181 (M 32U89+d). Other prominent ions were ob-
served at m/z 281 (M 390+a) and 241 (M 390+c) due to
the loss of the entire g-side chain containing a keto group at
C-15 and a reduced double bond at C-13,14 position. Other
strong signals were seen at m/z 278 (M 32U90), 266 (M
32U90+15), 247 (M 32U90+31), 217 and 191. The ¢nal
structure of K-tetranor-15-keto-13,14-dihydro-8-iso-PGF2K, a
major urinary metabolite of 8-iso-PGF2K, is shown in Fig. 4.
4. Discussion
This in vivo metabolism study of 8-iso-PGF2K in the rabbit
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Fig. 2. Representative RP-HPLC separation of plasma (left panel) and urine (right panel) at di¡erent times after i.v. administration of 1.24
MBq/22.2 Wg/kg (corresponding to 100 Wg) of [3H]8-iso-PGF2K to a rabbit. Known peaks are designated in the chromatogram.
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demonstrates that this compound eliminates from the circu-
lation very rapidly after a single intravenous administration of
unlabelled or tritium labelled 8-iso-PGF2K as described for
other cyclooxygenase catalysed prostaglandins [21,22]. Results
from the radio-HPLC and RIA after the administration of
both unlabelled and radiolabelled substances correlated well
with each other. After intravenous administration, a brief dis-
tribution phase with a half-life (K-phase) of about 1 min was
observed in the plasma. The terminal elimination phase half-
life (L-phase) was found to be about 4 min. Only 1.5 and 5 min
after administration 36% and 92% of tritium labelled 8-iso-
PGF2K was found to be as degraded metabolites of the parent
compound, respectively. It was previously shown that most of
the primary prostaglandins administered intravenously were
degraded within a few minutes [21^23].
It was also observed that most of the radioactivity excreted
via urine (about 80% during 4 h) mainly consists of several
degraded polar metabolites and a low percentage of the par-
ent compound. A certain amount of unmetabolised 8-iso-
PGF2K were also found in the urine when it was quanti¢ed
by a speci¢c radioimmunoassay as also seen in the radiochro-
matography of the labelled urinary samples. The excretion of
unmetabolised PGF2K or its major metabolite 15-keto-13,14-
dihydro-PGF2K had previously been described [24^26].
The RP-HPLC separation of 8-iso-PGF2K and its metabo-
lites in plasma shows that already 5 min after administration
8-iso-PGF2K had degraded to several metabolites. Twenty
minutes after administration most of the parent compound
was found to be metabolised to several other polar com-
pounds. Similar polar compounds were found in the urine
collected between 10^20 min. However, urine collected be-
tween 0^10 min contained only 8-iso-PGF2K (data not shown).
After 20 min most of the products found in the urine consist
of several L-oxidised products as identi¢ed by di¡erent chro-
matographic systems and also by GC-MS. One of the major
urinary metabolites was identi¢ed as K-tetranor-15-keto-
13,14-dihydro-8-iso-PGF2K. Several other polar metabolites
of 8-iso-PGF2K were also seen in the GC-MS analysis of the
urinary samples. However, no ¢nal structural determination
of these metabolites was possible due to the limited amounts
of the unlabelled puri¢ed compounds for further GC-MS
analysis. These unidenti¢ed polar metabolites are most prob-
ably various forms of L-oxidised products as seen for PGF2K
[22].
The metabolism of 8-iso-PGF2K to K-tetranor-15-keto-
13,14-dihydro-8-iso-PGF2K and other L-oxidised products oc-
curs in several steps in the rabbit which is very similar to
PGF2K metabolism in this species [21^23]. A tentative meta-
bolic pathway of 8-iso-PGF2K in the rabbit is shown in Fig. 4.
In vitro studies with tissue enzymes (unpublished observa-
tions, Basu) and in vivo experiments (this study) in plasma
show that oxidation of the 15-hydroxy group at C-15 by 15-
PGDH was the ¢rst step of 8-iso-PGF2K metabolism. A re-
duction of C-13,14 double bond by v13-reductase and forma-
tion of 15-keto-13,14-dihydro-8-iso-PGF2K was shown to oc-
cur in the second step of metabolism as previously
demonstrated for PGF2K metabolism in various species [21^
23]. Both L-oxidation and g-oxidation are very common steps
of prostaglandin metabolism. This study also clearly shows
that 15-keto-13,14-dihydro-8-iso-PGF2K rapidly metabolises
through L-oxidation mainly to K-tetranor-15-keto-13,14-dihy-
dro-8-iso-PGF2K and several other L-oxidised metabolites. L-
Oxidised metabolites of 8-iso-PGF2K was also identi¢ed in
human urine [15].
In conclusion, this study shows that 8-iso-PGF2K when ad-
ministered intravenously is metabolised mainly through dehy-
drogenation at C-15, reduction of C-13,14 double bond and L-
oxidation of the K-chain to several polar compounds and
eliminates rapidly from the circulation in a similar manner
as the other primary prostaglandins. One of the major urinary
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Fig. 3. Mass-spectrum of the methyl ester and TMS derivative of a
major urinary metabolite, K-tetranor-15-keto-13,14-dihydro-8-iso-
PGF2K (peak A, Fig. 2).
Fig. 4. Tentative metabolic pathway of 8-iso-PGF2K in the rabbit.
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metabolites of 8-iso-PGF2K in the rabbit is identi¢ed as
K-tetranor-15-keto-13,14-dihydro-8-iso-PGF2K. The plasma
elimination half-life was found to be short and a high recov-
ery of the radioactivity as determined by polar L-oxidised
compounds was observed in the urine. Unmetabolised 8-iso-
PGF2K was also found in the urine to some extent.
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